GRAIL, Inc.
Financials
Valuation Metrics
GRAIL, Inc.'s Market Cap is $5.97B. At end of 2025 it was $3.49B. Ranked #1158 of 3,118 in US market (top 37%), #377 of 1,474 on NASDAQ (top 26%), #79 of 203 in Health Care Equipment & Services (top 39%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.97B | US#1,158/3,118 Sec#79/203 |
| Revenue | $165M | US#2,585/3,118 Sec#172/203 |
| Net Income | $-392M | US—/3,118 Sec—/203 |
| Total Assets | $2.84B | US#1,850/3,118 Sec#90/203 |
| Net Assets | $2.54B | US#1,076/3,118 Sec#58/203 |
| Employees | 910 | US#2,017/3,118 Sec#140/203 |
| Value | ||
| P/B | 2.35x | US#1,580/3,118 Sec#77/203 |
| P/S | 36.15x | US#2,906/3,118 Sec#202/203 |
| FCF Yield | -4.94% | US—/3,118 Sec—/203 |
| Profitability | ||
| ROE | -15.40% | US#2,424/3,118 Sec#144/203 |
| ROA | -13.77% | US#2,716/3,118 Sec#163/203 |
| Op. Margin | -338.40% | US#2,764/3,118 Sec#197/203 |
| Revenue Growth | 23.07% | US#581/3,118 Sec#37/203 |
| Financial Health | ||
| Debt Ratio | 11.84% | US#130/3,118 Sec#9/203 |
| Total Debt | $91M | US#2,453/3,118 Sec#140/203 |
| FCF | $-295M | US#2,841/3,118 Sec#202/203 |
| Cash | $56M | US#2,537/3,118 Sec#162/203 |
| Current Ratio | 10.95x | US#219/3,118 Sec#8/203 |
| Performance | ||
| 1Y Return | 45.49% | US#402/3,118 Sec#43/203 |
| 1M Return | -6.64% | US#1,532/3,118 Sec#124/203 |
| From 52W High | -19.66% | US#1,092/3,118 Sec#88/203 |
| 1Y MDD | -62.92% | US#2,796/3,118 Sec#177/203 |
| Trading | ||
| Volume | 807,131 shares | US#1,546/3,118 Sec#97/203 |
| Trading Value | $112M | US#719/3,118 Sec#59/203 |
| Per Share | ||
| EPS | $-8.77 | US—/3,118 Sec—/203 |
| BPS | $56.93 | US#359/3,118 Sec#31/203 |
Company Info
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.